Charcot-Marie-Tooth Disease
Clinical guidelines for managing inherited neuropathies, evaluating PMP22 duplication, axonal and demyelinating electrodiagnostics, and reviewing physical and orthotic therapies.
🧠 Standard of Care & Symptoms
Charcot-Marie-Tooth Disease (CMT) is a heterogeneous group of progressive, inherited peripheral neuropathies. Characterized by slowly progressive motor and sensory dysfunction, it primarily affects the distal extremities.
- Presentation: Key clinical signs.
- *Distal Muscle Wasting:* Symmetrical wasting of intrinsic muscles of the feet and lower legs, leading to a classic "stork leg" or "inverted champagne bottle" appearance. Distal hand muscle wasting occurs in later stages.
- *Foot Deformities:* High-arched feet (**pes cavus**) and clawed toes (**hammer toes**) are hallmarks, caused by imbalance in intrinsic foot muscle strength.
- *Gait Abnormalities:* Weakness of ankle dorsiflexion causes a foot drop, resulting in a high-stepping, slapping gait.
- *Sensory Loss:* Slowly progressive, symmetrical sensory loss to vibration, pain, and temperature in a stocking-glove pattern.
- *Hyporeflexia:* Absent or markedly reduced deep tendon reflexes, particularly at the ankles.
🧬 Diagnostics & Genetic Pathophysiology
Diagnosis relies on electrophysiological nerve conduction studies, clinical presentation, and definitive multi-gene panels.
- Diagnostic Markers: Key criteria.
- Nerve Conduction Studies (NCS): Distinguishes between demyelinating (CMT1) and axonal (CMT2) forms. CMT1 shows severely reduced motor conduction velocities (<38 m/s in the median nerve), while CMT2 shows reduced amplitudes with near-normal velocities.
- Genetic Testing: Multi-gene panel sequencing isolates specific mutations. Duplication of the *PMP22* gene is the most common diagnostic finding.
Pathophysiology of Inherited Neuropathy
The degeneration of peripheral nerves is driven by distinct molecular defects, classifying CMT into demyelinating or axonal subtypes:
- CMT1 (Demyelinating Neuropathy): The most common form is **CMT1A**, accounting for 70% of cases. It is caused by a 1.4 Mb duplication on chromosome 17 containing the **PMP22** (Peripheral Myelin Protein 22) gene. Overexpression of PMP22 disrupts myelin assembly and maintenance. Repetitive demyelination and remyelination by Schwann cells produce a characteristic "onion bulb" histopathology.
- CMT2 (Axonal Neuropathy): Characterized by primary degeneration of the peripheral axon rather than the myelin sheath. **CMT2A** is the most common axonal form, driven by mutations in the *MFN2* (Mitofusin-2) gene. Mitofusin-2 regulates mitochondrial fusion and transport; its mutation halts axonal mitochondrial distribution, starving long motor and sensory axons.
💊 Symptom Management & Orthotics
No disease-modifying pharmacotherapy exists. Standard of care is supportive, focusing on physical therapy, orthotic devices, and surgical corrections.
Physical & Occupational Therapy
- Strengthening & Stretching: Low-impact aerobic conditioning and targeted stretching of the Achilles tendon help maintain joint range of motion and prevent contractures.
- Splints & Aids: Occupational therapy coordinates adaptive devices for fine motor tasks affected by hand intrinsic wasting.
Orthotics & Surgical Care
- Ankle-Foot Orthoses (AFOs): Lightweight, custom-molded AFOs are prescribed to stabilize the ankle, prevent foot drop, and reduce fall risk.
- Orthopedic Surgery: Indicated for severe, painful pes cavus or hammer toe deformities that do not respond to orthotic correction.
- Neurotoxic Medication Avoidance: Patients must strictly avoid neurotoxic drugs, particularly chemotherapeutics like **Vincristine**, which can trigger rapid, irreversible worsening of neuropathy.
🔬 Active Clinical Trials
Clinical trials are currently evaluating myelin-targeted therapies, gene replacement, and downstream pathway inhibitors.
Evaluating the efficacy of PXT3003, a fixed-dose oral combination of baclofen, naltrexone, and sorbitol. This combination acts synergistically to downregulate PMP22 gene transcription in Schwann cells.
Key Inclusion: Age 16 to 65, genetically confirmed CMT1A (PMP22 duplication), and mild-to-moderate symptoms.Investigating a one-time intrathecally administered AAV vector carrying a functional copy of the MFN2 gene to restore mitochondrial dynamics in spinal cord motor neurons.
Key Inclusion: Age 18 to 55, confirmed pathogenic mutation in the MFN2 gene, and baseline walking ability of > 100 meters.Evaluating an oral histone deacetylase 6 (HDAC6) inhibitor designed to promote tubulin acetylation, enhancing axonal transport dynamics to preserve distal motor units.
Key Inclusion: Age ≥ 18, diagnosed with CMT1A, CMT1B, or CMT2, and evidence of progressive distal weakness.🗺️ Next Steps After Diagnosis
If you have recently been diagnosed with Charcot-Marie-Tooth Disease, establish these clinical care pathways:
- Confirm Genetic Subtype: Genetic testing is crucial to verify if the inheritance is autosomal dominant, recessive, or X-linked, guiding family planning and clinical trial screening.
- Schedule a Physical Therapy Evaluation: Establish a regular low-impact exercise and stretching routine to preserve muscle length and joint mobility.
- Obtain Custom AFOs: Work with an orthotist to evaluate the need for custom ankle-foot orthoses to stabilize your gait and prevent falls.
- Review Medication Safety: Share your diagnosis with all prescribing physicians to ensure you strictly avoid neurotoxic drugs.
❓ Patient FAQ
Q: What is the difference between CMT1 and CMT2?
A: **CMT1** is a demyelinating disorder, meaning the protective myelin sheath surrounding the nerve is damaged, causing slow electrical signal conduction. **CMT2** is an axonal disorder, meaning the nerve fiber (axon) itself is damaged, reducing the strength of the electrical signal while the speed of conduction remains near normal.
Q: Will CMT affect my life expectancy?
A: For the vast majority of patients, CMT does not affect life expectancy. It is a slowly progressive condition that causes significant physical disabilities (particularly affecting mobility and hand function), but it rarely impacts breathing or other vital organs.